Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179017 | 0.98 | MAPT (0.38) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL13269472 | 0.96 | ALDH1A1 (0.41) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL450892 | 0.96 | MAPT (0.39) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL13269286 | 0.94 | ALDH1A1 (0.39) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL2045397 | 0.91 | ALDH1A1 (0.42) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL14899078 | 0.90 | MAPT (0.46) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL6356446 | 0.88 | GRIK1 (0.39) | MAPTALDH1A1NPSR1GLO1HSD17B10 | |
| SCHEMBL14899076 | 0.88 | MAPT (0.45) | MAPTALDH1A1NPSR1GLO1LMNA | |
| SCHEMBL20262505 | 0.83 | ALDH1A1 (0.37) | MAPTALDH1A1LMNAGAAKDM4E | |
| SCHEMBL24870690 | 0.82 | ADORA1 (0.40) | MAPTALDH1A1NPSR1GLO1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308563-B2 | Process for producing ethylene oligomers | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2019-06-04 | — | — | US | disclosed |
| US-20180170827-A1 | PROCESS FOR PRODUCING ETHYLENE OLIGOMERS | HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) | 2018-06-21 | — | — | US | disclosed |
| US-20180169642-A1 | CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2018-06-21 | — | — | US | disclosed |
| EP-1559710-B1 | Dipeptidyl peptidase IV inhibitors based on cyclopropyl-fused pyrrolidine, process for their preparation and their use | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| US-RE41149-E1 | Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1261586-B1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| US-6031102-A | Optically active pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5767127-A | BACTERICIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5587386-A | BACTERICIDES, MICROBIOCIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308563-B2 | Process for producing ethylene oligomers | OXER1, HAO2, ORC3 | MAPT 2725/4885ALDH1A1 1507/4885NPSR1 2694/4885 |
| US-20180169642-A1 | CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME | HACL2, HAO2, MSMO1 | MAPT 3710/4885ALDH1A1 1614/4885NPSR1 2922/4885 |
| US-20180170827-A1 | PROCESS FOR PRODUCING ETHYLENE OLIGOMERS | OXER1, HAO2, ORC3 | MAPT 2725/4885ALDH1A1 1507/4885NPSR1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.